See more : Allsec Technologies Limited (ALLSEC.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Nika BioTechnology, Inc. (NIKA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nika BioTechnology, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Max Co., Ltd. (6454.T) Income Statement Analysis – Financial Results
- Peach Property Group AG (PEAN.SW) Income Statement Analysis – Financial Results
- Dafeng TV Ltd. (6184.TW) Income Statement Analysis – Financial Results
- Central Automotive Products Ltd. (8117.T) Income Statement Analysis – Financial Results
- Storebrand ASA (SREDF) Income Statement Analysis – Financial Results
Nika BioTechnology, Inc. (NIKA)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Nika BioTechnology, Inc.
International Professional Trainings Group Limited provides online and face-to-face under-graduate and graduate university studies, professional training, study tours, and consulting services. Its programs include business baccalaureate, MBA and business PhD studies, baccalaureate, masters and PhD marketing studies, baccalaureate in hotel management, chartered accountant, certified financial planner, and registered financial analyst programs. The company was incorporated in 1999 and is based in North Las Vegas, Nevada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 85.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 85.22K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 0.00 | 3.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 64.83K | 183.72K | 14.71K | 8.91K | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | -114.09K | 230.17K | -2.41K | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 64.83K | 69.63K | 244.88K | 6.50K | 6.50K | 33.39K | 48.86K | 48.60K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 64.83K | 69.63K | 244.88K | 6.50K | 6.50K | 33.39K | 48.86K | 48.60K |
Cost & Expenses | 64.83K | 69.63K | 244.88K | 6.50K | 6.50K | 33.39K | 48.86K | 48.60K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 3.49K | 115.00 | 147.00 | 364.00 | 180.00 | 348.00 |
Depreciation & Amortization | 0.00 | 3.18M | 14.71K | 8.91K | 171.86K | 0.00 | 0.00 | 0.00 |
EBITDA | -64.83K | 0.00 | 0.00 | 0.00 | -6.50K | -33.39K | -48.86K | -48.60K |
EBITDA Ratio | 0.00% | 0.00% | -187.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -64.83K | -69.63K | -159.67K | -6.50K | -6.50K | -33.39K | -48.86K | -48.60K |
Operating Income Ratio | 0.00% | 0.00% | -187.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 0.00 | 0.00 | -146.27K | 0.00 | -147.00 | -364.00 | -134.00 | 3.26K |
Income Before Tax | -64.83K | -69.63K | -160.98K | -6.62K | -6.65K | -33.75K | -48.99K | -45.34K |
Income Before Tax Ratio | 0.00% | 0.00% | -188.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -3.18M | -14.71K | -8.91K | -171.86K | 0.00 | 0.00 | 0.00 |
Net Income | -64.83K | -69.63K | -160.98K | -6.62K | -6.65K | -33.75K | -48.99K | -45.34K |
Net Income Ratio | 0.00% | 0.00% | -188.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
Weighted Avg Shares Out | 876.12M | 876.09M | 876.09M | 876.09M | 876.09M | 2.56M | 2.44M | 2.44M |
Weighted Avg Shares Out (Dil) | 876.09M | 876.09M | 876.09M | 876.09M | 876.09M | 2.56M | 2.44M | 2.44M |
Nika Pharmaceuticals, Inc. (NIKA) Signed a Distribution Agreement for Nigeria
Source: https://incomestatements.info
Category: Stock Reports